The European Biotech Act

🚨 Biotech Act – Call for Evidence now open! 🚨

The European Commission aims to adopt a Biotech Act in the second half of 2026 🧬🏛️ – and the starting pistol has just been fired.

🗣️ Now is the moment to have your say and shape the future of EU biotech policy. The Call for Evidence is open for 4 weeks, inviting your feedback, ideas and real-world input from across the biotech ecosystem.

💡 The Act will span several sectors – agri, marine, industrial – but health biotech will be a central pillar, with major implications for clinical trials, biomanufacturing, and the use of AI and data.

📄 What’s in the Call for Evidence?

👨‍🎓 Europe leads in research, but struggles to bring innovation to market.
⏱️ It takes too long to get biotech products authorised and scaled.
💶 EU companies lack risk-tolerant capital – especially for scaling and late-stage investment.
🧪 Biomanufacturing and workforce skills are key bottlenecks.
🤖 AI, data and real-world evidence can boost competitiveness.

The new Act aims to tackle all this – while ensuring safety, sustainability and security.

📝 Submit your views here:
🔗https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/14627-Biotech-Act_en 

📅 Deadline: 11 June 2025